Percutaneous devices for left atrial appendage occlusion: A contemporary review

Area of Science:

• Cardiology
• Medical Devices
• Stroke Prevention

Background:

• Atrial fibrillation (AF) significantly increases stroke risk, with thrombi commonly forming in the left atrial appendage (LAA).
• Oral anticoagulants are standard for stroke prevention in non-valvular AF, but bleeding risks limit their use in some patients.
• Left atrial appendage occlusion (LAAO) presents an alternative stroke prevention strategy for anticoagulation-intolerant AF patients.

Purpose of the Study:

• To systematically review the literature on left atrial appendage occlusion (LAAO) devices.
• To evaluate the efficacy and safety of various LAAO devices for stroke prevention in atrial fibrillation patients.

Main Methods:

• Systematic literature review of studies on left atrial appendage occlusion (LAAO) devices.
• Analysis of data on device efficacy, safety, and patient outcomes.
• Comparison of percutaneous LAAO devices, including Watchman and Amplatzer.

Main Results:

• Percutaneous LAAO, particularly with the FDA-approved Watchman device, is non-inferior to warfarin for preventing ischemic stroke and systemic thromboembolism.
• LAAO demonstrates lower rates of hemorrhagic stroke, bleeding, and death compared to warfarin therapy.
• Surgical LAAO has a high failure rate and is only recommended during cardiac surgery.

Conclusions:

• Left atrial appendage occlusion (LAAO) is a viable alternative for stroke prevention in non-valvular AF patients unsuitable for anticoagulation.
• The Watchman device is a leading FDA-approved option for LAAO, showing comparable efficacy to warfarin with improved safety.
• Further research is needed on optimal post-LAAO antithrombotic therapy, which remains patient-specific.